alleen voor onderzoeksdoeleinden

SB216763 GSK-3 inhibitor

Name: SB216763
Brand: Selleck Chemicals
SKU: S1075
Rating: 5 (93 reviews)

Cat.nr.: S1075

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. This compound activates autophagy.

SB216763 GSK-3 inhibitor Chemical Structure

Chemische structuur

Molecuulgewicht: 371.22

Spring naar

Kwaliteitscontrole (Quality Control)

Batch: Zuiverheid: 99.98%

99.98

Gerelateerde doelwitten	PI3K Akt mTOR ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A PDK
Overig GSK-3 Inhibitoren	CHIR-99021 (Laduviglusib) Laduviglusib (CHIR-99021) Hydrochloride TWS119 CHIR-98014 GSK-3 Inhibitor IX (BIO) LY2090314 Tideglusib SB415286 AR-A014418 1-Azakenpaullone

Celkweek, behandeling & werkzame concentratie
(Cell Culture, Treatment & Working Concentration)

Cellijnen	Assaytype	Concentratie	Incubatietijd	Activiteitsbeschrijving	PMID
HEK293	Function assay			Glycogen synthase activity of HEK293 cells, inhibition of GSK3-beta, EC50=0.2μM	12941331
HEK293	Function assay			Effective concentration of compound against glycogen synthase kinase-3 in HEK293 cells, EC50=0.2μM	15149684
MIAPaCa2	Growth inhibition assay		72 hrs	Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay, IC50=25μM	19338355
ST14A	Function assay		6 hrs	Inhibition of GSK-3-beta-mediated Wnt signaling in human ST14A cells assessed as increase in accumulation of beta-casein around nucleus after 6 hrs by microscopic analysis	20708937
neural precursor cells	Function assay			Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	17417631
ReNcell VM	Antiproliferative assay	3 uM	72 hrs	Antiproliferative activity against human ReNcell VM cells assessed as reduction of cell proliferation at 3 uM after 72 hrs	20708937
HepG2	Function assay	34 uM	12 hrs	Increase in glucose incorporation in human HepG2 cells at 34 uM after 12 hrs by glucose assay	25467150
3T3L1	Function assay	34 uM	12 hrs	Increase in glucose incorporation in mouse 3T3L1 cells at 34 uM after 12 hrs by glucose assay	25467150
HepG2	Function assay	34 uM	12 hrs	Inhibition of GSK3beta in human HepG2 cells assessed as decrease in ratio of phosphorylated GS/GS at 34 uM after 12 hrs by Western blot analysis	25467150
Sf9	Function assay		30 min	Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting, IC50=0.03388μM	SANGER
human HDLM-2 cell	Growth inhibition assay			Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50=0.20984 μM	SANGER
human NCI-H1770 cell	Growth inhibition assay			Inhibition of human NCI-H1770 cell growth in a cell viability assay. IC50=0.29392 μM	SANGER
human HOP-62 cell	Growth inhibition assay			Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=0.85256 μM	SANGER
human JAR cell	Growth inhibition assay			Inhibition of human JAR cell growth in a cell viability assay, IC50=1.21044 μM	SANGER
human K5 cell	Growth inhibition assay			Inhibition of human K5 cell growth in a cell viability, IC50=1.53698 μM	SANGER
human MV-4-11 cell	Growth inhibition assay			Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=2.69685 μM	SANGER
human BT-549 cell	Growth inhibition assay			Inhibition of human BT-549 cell growth in a cell viability assay, IC50=5.29376 μM	SANGER
human LB2241-RCC cell	Growth inhibition assay			Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=6.42874 μM	SANGER
human GAMG cell	Growth inhibition assay			Inhibition of human GAMG cell growth in a cell viability assay, IC50=6.65409 μM	SANGER
human HMV-II cell	Growth inhibition assay			Inhibition of human HMV-II cell growth in a cell viability assay, IC50=7.67607 μM	SANGER
human RS4-11 cell	Growth inhibition assay			Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=8.24141 μM	SANGER
human NCI-H1993 cell	Growth inhibition assay			Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50=8.36534 μM	SANGER
human IST-SL1 cell	Growth inhibition assay			Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=9.0204 μM	SANGER
human SK-OV-3 cell	Growth inhibition assay			Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=9.1002 μM	SANGER
human ESS-1 cell	Growth inhibition assay			Inhibition of human ESS-1 cell growth in a cell viability assay, IC50=9.59872 μM	SANGER
human G-361 cell	Growth inhibition assay			Inhibition of human G-361 cell growth in a cell viability assay, IC50=10.1798 μM	SANGER
human ALL-PO cell	Growth inhibition assay			Inhibition of human ALL-PO cell growth in a cell viability assay, IC50=10.3477 μM	SANGER
human NB5 cell	Growth inhibition assay			Inhibition of human NB5 cell growth in a cell viability assay, IC50=11.2157 μM	SANGER
human DU-145 cell	Growth inhibition assay			Inhibition of human DU-145 cell growth in a cell viability assay, IC50=11.6535 μM	SANGER
human NMC-G1 cell	Growth inhibition assay			Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=11.7264 μM	SANGER
human RPMI-7951 cell	Growth inhibition assay			Inhibition of human RPMI-7951 cell growth in a cell viability assay. IC50=11.7864 μM	SANGER
human NCI-H2009 cell	Growth inhibition assay			Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=13.2427 μM	SANGER
human LoVo cell	Growth inhibition assay			Inhibition of human LoVo cell growth in a cell viability assay, IC50=13.3771 μM	SANGER
human A2058 cell	Growth inhibition assay			Inhibition of human A2058 cell growth in a cell viability assay, IC50=13.469 μM	SANGER
human D-566MG cell	Growth inhibition assay			Inhibition of human D-566MG cell growth in a cell viability assay, IC50=13.9481 μM	SANGER
human QIMR-WIL cell	Growth inhibition assay			Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=15.6394 μM	SANGER
human S-117 cell	Growth inhibition assay			Inhibition of human S-117 cell growth in a cell viability assay, IC50=16.4022 μM	SANGER
human YH-13 cell	Growth inhibition assay			Inhibition of human YH-13 cell growth in a cell viability assay, IC50=16.6865 μM	SANGER
human IGROV-1 cell	Growth inhibition assay			Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=17.2001 μM	SANGER
human BHT-101 cell	Growth inhibition assay			Inhibition of human BHT-101 cell growth in a cell viability assay, IC50=17.6099 μM	SANGER
human MKN45 cell	Growth inhibition assay			Inhibition of human MKN45 cell growth in a cell viability assay, IC50=18.4128 μM	SANGER
human A498 cell	Growth inhibition assay			Inhibition of human A498 cell growth in a cell viability assay, IC50=19.4549 μM	SANGER
human U-266 cell	Growth inhibition assay			Inhibition of human U-266 cell growth in a cell viability assay, IC50=20.8797 μM	SANGER
human BFTC-905 cell	Growth inhibition assay			Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=21.1879 μM	SANGER
human BxPC-3 cell	Growth inhibition assay			Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50=21.3554 μM	SANGER
human NCI-SNU-1 cell	Growth inhibition assay			Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50=21.5558 μM	SANGER
human SF539 cell	Growth inhibition assay			Inhibition of human SF539 cell growth in a cell viability assay, IC50=22.0198 μM	SANGER
human VA-ES-BJ cell	Growth inhibition assay			Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50=22.5763 μM	SANGER
human HuO-3N1 cell	Growth inhibition assay			Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=22.6151 μM	SANGER
human EM-2 cell	Growth inhibition assay			Inhibition of human EM-2 cell growth in a cell viability assay, IC50=22.6689 μM	SANGER
human T98G cell	Growth inhibition assay			Inhibition of human T98G cell growth in a cell viability assay, IC50=23.3009 μM	SANGER
human SW1783 cell	Growth inhibition assay			Inhibition of human SW1783 cell growth in a cell viability assay, IC50=23.5243 μM	SANGER
human NKM-1 cell	Growth inhibition assay			Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=23.8512 μM	SANGER
human KOSC-2 cell	Growth inhibition assay			Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50=24.1292 μM	SANGER
human SW48 cell	Growth inhibition assay			Inhibition of human SW48 cell growth in a cell viability assay, IC50=24.6067 μM	SANGER
human NCI-H28 cell	Growth inhibition assay			Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50=25.2104 μM	SANGER
human 5637 cell	Growth inhibition assay			Inhibition of human 5637 cell growth in a cell viability assay, IC50=25.8111 μM	SANGER
human NB69 cell	Growth inhibition assay			Inhibition of human NB69 cell growth in a cell viability assay, IC50=26.1764 μM	SANGER
human HT-29 cell	Growth inhibition assay			Inhibition of human HT-29 cell growth in a cell viability assay, IC50=27.1752 μM	SANGER
human PFSK-1 cell	Growth inhibition assay			Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50=27.593 μM	SANGER
human UACC-257 cell	Growth inhibition assay			Inhibition of human UACC-257 cell growth in a cell viability assay, IC50=27.743 μM	SANGER
human D-423MG cell	Growth inhibition assay			Inhibition of human D-423MG cell growth in a cell viability assay, IC50=27.9106 μM	SANGER
human NH-12 cell	Growth inhibition assay			Inhibition of human NH-12 cell growth in a cell viability assay, IC50=28.4059 μM	SANGER
human DEL cell	Growth inhibition assay			Inhibition of human DEL cell growth in a cell viability assay, IC50=29.0474 μM	SANGER
human LS-513 cell	Growth inhibition assay			Inhibition of human LS-513 cell growth in a cell viability assay, IC50=30.1334 μM	SANGER
human NBsusSR cell	Growth inhibition assay			Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=30.5678 μM	SANGER
human BV-173 cell	Growth inhibition assay			Inhibition of human BV-173 cell growth in a cell viability assay, IC50=30.7649 μM	SANGER
human A101D cell	Growth inhibition assay			Inhibition of human A101D cell growth in a cell viability assay, IC50=30.9784 μM	SANGER
human LU-134-A cell	Growth inhibition assay			Inhibition of human LU-134-A cell growth in a cell viability assay, IC50=31.0238 μM	SANGER
human ES3 cell	Growth inhibition assay			Inhibition of human ES3 cell growth in a cell viability assay, IC50=31.3376 μM	SANGER
human NY cell	Growth inhibition assay			Inhibition of human NY cell growth in a cell viability assay, IC50=32.2965 μM	SANGER
human NCI-H1975 cell	Growth inhibition assay			Inhibition of human NCI-H1975 cell growth in a cell viability assay, IC50=32.3582 μM	SANGER
human A704 cell	Growth inhibition assay			Inhibition of human A704 cell growth in a cell viability assay, IC50=34.2059 μM	SANGER
human SK-MEL-24 cell	Growth inhibition assay			Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50=34.2523 μM	SANGER
human SW1088 cell	Growth inhibition assay			Inhibition of human SW1088 cell growth in a cell viability assay, IC50=34.3452 μM	SANGER
human SK-MEL-1 cell	Growth inhibition assay			Inhibition of human SK-MEL-1 cell growth in a cell viability, IC50=34.714 μM	SANGER
human MOLT-4 cell	Growth inhibition assay			Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=36.1467 μM	SANGER
human T47D cell	Growth inhibition assay			Inhibition of human T47D cell growth in a cell viability assay, IC50=37.1647 μM	SANGER
human SW1710 cell	Growth inhibition assay			Inhibition of human SW1710 cell growth in a cell viability assay, IC50=37.3608 μM	SANGER
human MKN7 cell	Growth inhibition assay			Inhibition of human MKN7 cell growth in a cell viability assay, IC50=38.0909 μM	SANGER
human CAL-72 cell	Growth inhibition assay			Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=38.1178 μM	SANGER
human AGS cell	Growth inhibition assay			Inhibition of human AGS cell growth in a cell viability assay, IC50=38.2039 μM	SANGER
human BE-13 cell	Growth inhibition assay			Inhibition of human BE-13 cell growth in a cell viability assay, IC50=38.7783 μM	SANGER
human Calu-6 cell	Growth inhibition assay			Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=39.6964 μM	SANGER
human CAL-27 cell	Growth inhibition assay			Inhibition of human CAL-27 cell growth in a cell viability assay, IC50=44.0054 μM	SANGER
human BB49-HNC cell	Growth inhibition assay			Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=44.0278 μM	SANGER
Klik om meer experimentele gegevens over cellijnen te bekijken

Chemische informatie, opslag en stabiliteit (Chemical Information, Storage & Stability)

Molecuulgewicht	371.22	Formule	C₁₉H₁₂N₂O₂Cl₂	Opslag (vanaf de datum van ontvangst)	3 jaar-20°Cpoeder
CAS-nr.	280744-09-4	SDF downloaden		Opslag van stamoplossingen	1 jaar-80°Cin oplosmiddel 1 maand-20°Cin oplosmiddel
Synoniemen	N/A			Smiles	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl

Oplosbaarheid (Solubility)

In vitro
Batch:

DMSO : 23 mg/mL (61.95 mM)
(Met vocht verontreinigd DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molariteitscalculator

Massa	Concentratie	Volume	Molecuulgewicht
=	×	×

Verdunningscalculator Molecuulgewichtcalculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Gevalideerd door Selleck labs. Mocht u aanpassingen aan deze formulering nodig hebben, neem dan contact op met ons verkoopteam voor aangepaste tests.	4.000mg/ml (10.78mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo formulatiecalculator (heldere oplossing)

Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)

Dosering: mg/kg Gemiddeld gewicht van dieren: g Doseervolume per dier:μL Aantal dieren:

Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berekeningsresultaten:

Werkconcentratie: mg/ml;

Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH₂O, mengen en verhelderen.

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.

Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.

Werkingsmechanisme (Mechanism of Action)

Targets/IC₅₀/Ki	GSK-3α (Cell-free assay) 34.3 nM GSK-3β (Cell-free assay) ~34.3 nM
In vitro	SB 216763 displays similar potency for GSK-3β with 96% inhibition at 10 μM while exhibiting minimal activity against 24 other protein kinases including PKBα and PDK1 with IC50 of >10 μM. This compound stimulates glycogen synthesis in human liver cells with EC50 of 3.6 μM, and induces dose-dependent transcription of a β-catenin-LEF/TCF regulated reporter gene in HEK293 cells with a maximum 2.5-fold induction at 5 μM. It protects the cerebellar granule neurones from apoptotic cell death induced by LY-294002 or potassium-deprivation in a concentration-dependent manner, with a maximal neuroprotection at 3 μM in contrast with the effect of lithium chloride at which 10 mM is required. This chemical at 3 μM also completely prevents death of chicken dorsal root ganglion sensory neurones induced by LY-294002 regardless of NGF. It treatment at 5 μM markedly inhibits the GSK-3-dependent phosphorylation of neuronal-specific microtubule-associated protein tau in cerebellar granule neurones or recombinant tau in HEK293 cells, and induces increased levels of cytoplasmic β-catenin in both cells mimicking the effect of Wnt-mediated inhibition of GSK-3. In pancreatic cancer cell lines including BXPC-3, MIA-PaCa2, PANC1, ASPC1, and CFPAC, this compound treatment at 25-50 μM reduces cell viability in a dose-dependent manner, and leads to significant increase in apoptosis by 50% at 72 hours due to the specific down regulation of GSK-3β, while has no effect in HMEC or WI38 cell lines.
Kinase Assay	GSK-3 activiteitsbepaling
Kinase Assay	De GSK-3 kinaseactiviteit wordt gemeten, in aanwezigheid van verschillende concentraties SB 216763, in een reactiemengsel dat eindconcentraties bevat van 1 nM humane GSK-3α, 50 mM MOPS pH 7.0, 0,2 mM EDTA, 10 mM Mg-acetaat, 7,5 mM β-mercaptoethanol, 5% (w/v) glycerol, 0,01% (w/v) Tween-20, 10% (v/v) DMSO, en 28 μM GS-2 peptide substraat. De GS-2 peptide sequentie komt overeen met een regio van glycogeensynthase die wordt gefosforyleerd door GSK-3. De bepaling wordt geïnitieerd door de toevoeging van 0,34 μCi [³³P]γ-ATP. De totale ATP-concentratie is 10 μM. Na 30 minuten incubatie bij kamertemperatuur wordt de bepaling gestopt door de toevoeging van een derde bepalingsvolume van 2,5% (v/v) H₃PO₄ dat 21 mM ATP bevat. Monsters worden aangebracht op P30 fosfocellulosematten en zes keer gewassen in 0,5% (v/v) H₃PO₄. De filtermatten worden in monsterzakken geseald die Wallac betaplate scintillatievloeistof bevatten. De ³³P-inbouw in het substraatpeptide wordt bepaald door de matten te tellen in een Wallac microbeta scintillatieteller.
In vivo	Administration of SB 216763 at 20 mg/kg significantly prevents lung inflammation and the subsequent fibrosis in bleomycin (BLM)-induced pulmonary inflammation and fibrosis model in mice by significantly blocking the production of inflammatory cytokines MCP-1 and TNF-α by macrophages, and significantly improves the survival of BLM-treated mice. This compound treatment causes a significant reduction in BLM-induced alveolitis by inhibiting alveolar epithelial cell damage.
Referenties	[1] https://pubmed.ncbi.nlm.nih.gov/11033082/ [2] https://pubmed.ncbi.nlm.nih.gov/11279265/ [3] https://pubmed.ncbi.nlm.nih.gov/15781615/ [4] https://pubmed.ncbi.nlm.nih.gov/19959748/

Toepassingen (Applications)

Methoden	Biomarkers	Afbeeldingen	PMID
Western blot	c-Myb pGSK-3β / GSK-3β / E2F1 / β-catenin		21795403
Growth inhibition assay	Cell viability		24779365

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):